The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Hygroton     2-chloro-5-(1-hydroxy-3-oxo- 2H-isoindol-1...

Synonyms: Higroton, Oxodolin, Zambesil, Oxodoline, Thalitone, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Chlorphthalidolone


Psychiatry related information on Chlorphthalidolone


High impact information on Chlorphthalidolone


Chemical compound and disease context of Chlorphthalidolone


Biological context of Chlorphthalidolone


Anatomical context of Chlorphthalidolone

  • The affinity of chlorthalidone for red blood cells was further evidenced on incubation of 14C-chlorthalidone with human blood [21].
  • Preincubation of the blood samples with acetazolamide prior to the addition of 14C-chlorthalidone, as well as incubation of acetozolamide in blood samples previously incubated with 14C-chlorthalidone, demonstrated that acetazolamide is able to inhibit and to displace chlorthalidone from blood cells [21].
  • Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study [22].
  • Non-use of chlorthalidone was associated with bone loss at the calcaneus (-0.56% per year) and the proximal radius (-0.91% per year); borderline bone gain was observed at the distal radius (+0.39%) [23].
  • In 12 patients with essential hypertension who remained hypertensive despite chronic chlorthalidone treatment, the effect of 2 weeks of additional therapy with the converting enzyme inhibitor (CEI) enalapril on blood pressure and body fluid volumes has been evaluated [24].

Associations of Chlorphthalidolone with other chemical compounds


Gene context of Chlorphthalidolone


Analytical, diagnostic and therapeutic context of Chlorphthalidolone


  1. Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy. Blaufox, M.D., Lee, H.B., Davis, B., Oberman, A., Wassertheil-Smoller, S., Langford, H. JAMA (1992) [Pubmed]
  2. Incidence of chlorthalidone-induced hypercalcemia. Palmer, F.J. JAMA (1978) [Pubmed]
  3. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Rahman, M., Pressel, S., Davis, B.R., Nwachuku, C., Wright, J.T., Whelton, P.K., Barzilay, J., Batuman, V., Eckfeldt, J.H., Farber, M., Henriquez, M., Kopyt, N., Louis, G.T., Saklayen, M., Stanford, C., Walworth, C., Ward, H., Wiegmann, T. Arch. Intern. Med. (2005) [Pubmed]
  4. Effects of chlorthalidone on ventricular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. Cabral, A.M., Carvalhinho, F.B., Vasquez, E.C., Cicilini, M.A. Hypertension (1994) [Pubmed]
  5. Effect of antihypertensive agents on quality of life in the elderly. Fogari, R., Zoppi, A. Drugs & aging. (2004) [Pubmed]
  6. One year efficacy and tolerability of oxprenolol slow-release and chlorthalidone on fixed combination in mild to moderate hypertension. Masoni, A., Tomasi, A.M., Pirani, R., Lazzaretto, R., Ambroso, G. Giornale italiano di cardiologia. (1981) [Pubmed]
  7. Chlorthalidone in hypoparathyroidism. McCarron, D.A. N. Engl. J. Med. (1978) [Pubmed]
  8. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. Grimm, R.H., Flack, J.M., Grandits, G.A., Elmer, P.J., Neaton, J.D., Cutler, J.A., Lewis, C., McDonald, R., Schoenberger, J., Stamler, J. JAMA (1996) [Pubmed]
  9. Menopause-dependent plasma lipoprotein alterations in diuretic-treated women. Boehringer, K., Weidmann, P., Mordasini, R., Schiffl, H., Bachmann, C., Riesen, W. Ann. Intern. Med. (1982) [Pubmed]
  10. Dopamine beta-hydroxylase and plasma renin activity in patients with low-, normal-, and high-renin essential hypertension. Lawton, W.J., Fitz, A., Grant, C., Witte, D.L. Circulation (1979) [Pubmed]
  11. Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Barzilay, J.I., Davis, B.R., Cutler, J.A., Pressel, S.L., Whelton, P.K., Basile, J., Margolis, K.L., Ong, S.T., Sadler, L.S., Summerson, J. Arch. Intern. Med. (2006) [Pubmed]
  12. Effect of salt depletion and propranolol on blood pressure and plasma renin activity in various forms of hypertension. Geyskes, G.G., Boer, P., Vos, J., Leenen, F.H., Mees, E.J. Circ. Res. (1975) [Pubmed]
  13. Evidence for the efficacy of low-dose diuretic monotherapy. Flack, J.M., Cushman, W.C. Am. J. Med. (1996) [Pubmed]
  14. Renin reactivity as a determinant of responsiveness to antihypertensive treatment. Weber, M.A., Lopez-Ovejero, J.A., Drayer, J.I., Case, D.B., Laragh, J.H. Arch. Intern. Med. (1977) [Pubmed]
  15. Metoprolol with and without chlorthalidone in hypertension. Kubik, M., Kendall, M., Ebbutt, A., John, V. Clin. Pharmacol. Ther. (1979) [Pubmed]
  16. Clonidine and guanfacine in hypertension. Jain, A.K., Hiremath, A., Michael, R., Ryan, J.R., McMahon, F.G. Clin. Pharmacol. Ther. (1985) [Pubmed]
  17. Atenolol and chlorthalidone on blood pressure, heart rate, and plasma renin activity in hypertension. Teeuw, A.H., Leenen, F.H., Geyskes, G.G., Boer, P. Clin. Pharmacol. Ther. (1979) [Pubmed]
  18. Doxazosin induces activation of GADD153 and cleavage of focal adhesion kinase in cardiomyocytes en route to apoptosis. Eiras, S., Fernández, P., Piñeiro, R., Iglesias, M.J., González-Juanatey, J.R., Lago, F. Cardiovasc. Res. (2006) [Pubmed]
  19. Effects of competitive red blood cell binding and reduced hematocrit on the blood and plasma levels of [14C]Indapamide in the rat. Lettieri, J.T., Portelli, S.T. J. Pharmacol. Exp. Ther. (1983) [Pubmed]
  20. Pharmacokinetics of chlorthalidone in the elderly after single and multiple doses. Colussi, D., Schoeller, J.P., Richard, A., Sioufi, A. British journal of clinical pharmacology. (1983) [Pubmed]
  21. Binding-site interaction of chlorthalidone and acetazolamide, two drugs transported by red blood cells. Beermann, B., Hellström, K., Lindström, B., Rosén, A. Clin. Pharmacol. Ther. (1975) [Pubmed]
  22. Diuretics, potassium and arrhythmias in hypertensive coronary disease. Ikram, H., Espiner, E.A., Nicholls, M.G. Drugs (1986) [Pubmed]
  23. A randomized, double-masked, placebo-controlled trial of chlorthalidone and bone loss in elderly women. Wasnich, R.D., Davis, J.W., He, Y.F., Petrovich, H., Ross, P.D. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. (1995) [Pubmed]
  24. Changes in haemodynamics and body fluid volume due to enalapril in patients with essential hypertension on chronic diuretic therapy. van Schaik, B.A., Geyskes, G.G., Boer, P., Dorhout Mees, E.J. Eur. J. Clin. Pharmacol. (1986) [Pubmed]
  25. Crossover design to test antihypertensive drugs with self-recorded blood pressure. Ménard, J., Serrurier, D., Bautier, P., Plouin, P.F., Corvol, P. Hypertension (1988) [Pubmed]
  26. Low-dose captopril therapy in mild and moderate hypertension. Randomized comparison of twice daily vs three times daily doses. Corea, L., Bentivoglio, M., Verdecchia, P. Hypertension (1983) [Pubmed]
  27. Can simple clinical measurements detect patient noncompliance? Haynes, R.B., Taylor, D.W., Sackett, D.L., Gibson, E.S., Bernholz, C.D., Mukherjee, J. Hypertension (1980) [Pubmed]
  28. Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators. Rosei, E.A., Dal Palù, C., Leonetti, G., Magnani, B., Pessina, A., Zanchetti, A. J. Hypertens. (1997) [Pubmed]
  29. The treatment of obese hypertensive black women: a comparative study of chlorthalidone versus clonidine. Reisin, E., Weed, S.G. J. Hypertens. (1992) [Pubmed]
  30. Effects of antihypertensive agents propranolol, metoprolol, nadolol, prazosin, and chlorthalidone on ACAT activity in rabbit and rat aortas and on LCAT activity in human plasma in vitro. Bell, F.P. J. Cardiovasc. Pharmacol. (1985) [Pubmed]
  31. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. Perry, H.M., Smith, W.M., McDonald, R.H., Black, D., Cutler, J.A., Furberg, C.D., Greenlick, M.R., Kuller, L.H., Schnaper, H.W., Schoenberger, J.A. Stroke (1989) [Pubmed]
  32. Secondary hyperparathyroidism in idiopathic renal hypercalciuria: fact or theory? Burckhardt, P., Jaeger, P. J. Clin. Endocrinol. Metab. (1981) [Pubmed]
  33. Characteristics of participants at baseline in the Treatment of Mild Hypertension Study (TOMHS). Mascioli, S.R., Grimm, R.H., Neaton, J.D., Stamler, J., Prineas, R.J., Cutler, J.A., Elmer, P.J., McDonald, R., Schnaper, H., Schoenberger, J. Am. J. Cardiol. (1990) [Pubmed]
  34. Treatment of hypoparathyroid patients with chlorthalidone. Porter, R.H., Cox, B.G., Heaney, D., Hostetter, T.H., Stinebaugh, B.J., Suki, W.N. N. Engl. J. Med. (1978) [Pubmed]
  35. Efficacy and reduced metabolic side effects of a 15-mg chlorthalidone formulation in the treatment of mild hypertension. A multicenter study. Vardan, S., Mehrotra, K.G., Mookherjee, S., Willsey, G.A., Gens, J.D., Green, D.E. JAMA (1987) [Pubmed]
  36. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Wassertheil-Smoller, S., Blaufox, M.D., Oberman, A., Davis, B.R., Swencionis, C., Knerr, M.O., Hawkins, C.M., Langford, H.G. Ann. Intern. Med. (1991) [Pubmed]
  37. Responsiveness of hypercalciuria to thiazide in Dent's disease. Raja, K.A., Schurman, S., D'mello, R.G., Blowey, D., Goodyer, P., Van Why, S., Ploutz-Snyder, R.J., Asplin, J., Scheinman, S.J. J. Am. Soc. Nephrol. (2002) [Pubmed]
  38. Tolerability, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics. Weir, M.R., Flack, J.M., Applegate, W.B. Am. J. Med. (1996) [Pubmed]
WikiGenes - Universities